To test the efficacy of this approach in vivo, xenograft mice implanted with the ovarian cancer line, OVCAR3, were treated with cisplatin and an EZH2 inhibitor, GSK126, separately and in combination. Here, EZH2 is linked to ovarian carcinoma.